Nanoparticle Ferry Delivers Inflammation-Resolving Molecule to Spinal Cord to Rewire Pain at Its Source

Neuropathic pain, the burning, electric, or shooting pain that follows nerve injury, afflicts roughly one in ten people and remains one of medicine’s most stubborn therapeutic challenges. Current first-line drugs—tricyclic antidepressants, gabapentinoids, and serotonin-norepinephrine reuptake inhibitors—dull symptoms for some patients but often bring dose-limiting side effects ranging from nausea to cardiotoxicity, while opioids carry well-known risks of addiction. Now, a team of researchers writing in Materials Today Bio has unveiled a two-pronged advance: they have mapped a previously unknown molecular circuit that drives inflammatory pain in the spinal cord, and they have engineered a targeted nanocarrier that delivers a healing molecule straight to the immune cells that run that circuit—all through a simple intravenous injection.

The story begins with microglia, the resident immune cells of the central nervous system. Under healthy conditions, microglia patrol the spinal cord and support tissue repair. After a nerve injury, however, many of them flip into a pro-inflammatory state, pumping out signaling molecules such as tumor necrosis factor, interleukin-6, and interleukin-1β that amplify pain signals. The researchers behind the new study, working with a mouse model of spared nerve injury, showed that this polarization shift is a central pathological node in neuropathic pain—and that coaxing microglia back toward an anti-inflammatory, pro-repair state can meaningfully relieve hypersensitivity to both mechanical touch and cold.

Their therapeutic tool of choice was aspirin-triggered resolvin D1, or AT-RvD1, a member of the specialized pro-resolving mediators. These are not conventional anti-inflammatory drugs that simply suppress the immune response; they are lipid messengers derived from omega-3 fatty acids that actively terminate inflammation and restore tissue homeostasis. AT-RvD1 itself is a 17R-hydroxylated derivative of docosahexaenoic acid, produced in the body when aspirin-acetylated cyclooxygenase-2 reroutes DHA metabolism toward resolution. Earlier work had hinted that AT-RvD1 could calm neuroinflammation in the spinal dorsal horn, but the molecular machinery it engaged remained obscure, and the molecule’s clinical promise was hobbled by rapid degradation in the bloodstream and the invasiveness of direct spinal injection.

To find the missing mechanism, the team turned to computational and molecular detective work. Mining a publicly available gene-expression dataset from a spinal nerve ligation model, they identified angiopoietin-like protein 4, or ANGPTL4, as a gene sharply upregulated in injured spinal cords. Subsequent experiments in BV2 microglial cells confirmed the pattern: inflammatory stimulation with lipopolysaccharide drove ANGPTL4 expression upward, and AT-RvD1 pulled it back down. The functional stakes became clear when the researchers manipulated ANGPTL4 directly. Silencing it with small interfering RNA suppressed pro-inflammatory cytokines, while overexpressing it—either in cultured cells or via adeno-associated virus in injured mice—fanned the inflammatory flames, pushed microglia toward the pro-inflammatory CD86-positive state, and blunted AT-RvD1’s analgesic effects. ANGPTL4, in short, was a linchpin.

The next question was how ANGPTL4 exerts its influence. Quantitative proteomics of treated microglia pointed the investigators toward propionate metabolism, and gas chromatography–mass spectrometry revealed that AT-RvD1 significantly raised propionate concentrations in the injured spinal cord. Immunoprecipitation coupled with mass spectrometry then identified SUCLG1, a key enzyme of the tricarboxylic acid cycle and propionate metabolism, as a physical binding partner of ANGPTL4. Co-immunoprecipitation and confocal imaging confirmed the interaction, and molecular docking revealed specific hydrogen bonds between the two proteins. The picture that emerged was elegant: ANGPTL4 binds SUCLG1 and shields it from ubiquitin-proteasome degradation, keeping the enzyme abundant. When AT-RvD1 suppresses ANGPTL4, SUCLG1 loses its protector, becomes polyubiquitinated, and is dismantled by the proteasome—shifting the spinal metabolic environment toward higher propionate, which the team showed is itself anti-inflammatory.

The metabolic logic checked out in both directions. Adding sodium propionate to AT-RvD1 treatment suppressed inflammatory proteins in microglia more strongly than the resolvin alone, and in injured mice the combination further reduced spinal inflammation and eased mechanical and cold allodynia. In a Transwell co-culture system pairing microglia with HT22 neurons, AT-RvD1-treated microglia passed along less inflammatory signaling to their neuronal neighbors, an effect amplified by propionate. The researchers had, in effect, charted a complete signaling axis—AT-RvD1 to ANGPTL4 to SUCLG1 to propionate—linking a lipid mediator of resolution to a metabolic switch that reprograms immune cells in the pain-processing centers of the spinal cord.

But a mechanism is only half a therapy. AT-RvD1 is fragile, degraded quickly in vivo, and getting it into the spinal cord conventionally requires intrathecal injection—a highly invasive procedure unsuited to repeated long-term dosing. The team’s solution was a liposomal nanocarrier decorated with MG1, a peptide that selectively recognizes activated microglia. Built from soy phosphatidylcholine, cholesterol, and a PEGylated lipid conjugated to the peptide, the resulting particles, dubbed A@Lipo-MG1, measured roughly 71 nanometers in diameter with a strongly negative surface charge, uniform size distribution, and spherical morphology confirmed by transmission electron microscopy. Nuclear magnetic resonance verified the peptide conjugation, and release studies showed a controlled profile, with more than half of the encapsulated AT-RvD1 released over four hours.

The targeting performance was striking. In cultured BV2 cells, rhodamine-labeled MG1-modified liposomes were taken up far more efficiently than unmodified versions, and the particles dampened inflammatory protein expression in a dose-dependent manner. In a laboratory model of the blood–spinal cord barrier, the modified liposomes crossed more readily, and pre-blocking with free MG1 peptide erased the advantage—strong evidence that the peptide was doing the recognition work. In injured mice, intravenously injected IR780-labeled MG1 liposomes lit up the spinal cord at six and twenty-four hours far more brightly than unmodified carriers, and confocal microscopy showed the fluorescent cargo accumulating inside Iba1-positive microglia in the spinal dorsal horn. Liquid chromatography–tandem mass spectrometry confirmed that A@Lipo-MG1 delivered the highest spinal AT-RvD1 concentrations of any formulation tested.

Functionally, the payoff was decisive. Intravenous free AT-RvD1 produced only a minimal analgesic effect, but the targeted liposomal formulation significantly alleviated mechanical hypersensitivity in the nerve-injured mice while reducing spinal mRNA and protein levels of interleukin-6, interleukin-1β, and tumor necrosis factor. Safety profiling showed no abnormalities in liver or kidney function biomarkers, and histological examination of heart, liver, spleen, lung, and kidney revealed no structural damage or inflammatory infiltration. The authors are candid about limitations: they did not resolve exactly how ANGPTL4 inhibits SUCLG1 ubiquitination, the precise binding interface remains unmapped, and only male mice were studied, leaving sex-dependent effects unexplored. Long-term pharmacokinetics in larger animals also await testing.

Even with those caveats, the study lands at a compelling intersection of immunology, metabolism, and nanomedicine. It elevates ANGPTL4 from a lipid-metabolism curiosity to a druggable node in spinal neuroinflammation, ties microglial polarization to a concrete metabolic handle in propionate, and demonstrates that a rationally designed, peptide-targeted liposome can ferry an unstable resolution mediator across biological barriers to the exact cells that need it. For the millions of patients whose pain outlasts their injuries and resists conventional drugs, the prospect of an intravenous therapy that does not merely mute pain signals but actively resolves the inflammation driving them is a genuinely new chapter—one that now has a defined molecular axis, a workable delivery vehicle, and a clear path toward translational testing.

Subject of Research: Targeted liposomal delivery of aspirin-triggered resolvin D1 to reprogram spinal microglia via the ANGPTL4-SUCLG1-propionate axis for neuropathic pain treatment

Article Title: AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

Article References: Wu, K., Gao, C., Fu, S., Li, Y., Li, Z., Han, X., Zhang, Y., Zhang, Y., & Wang, Y. (2026). AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain. Materials Today Bio, 41, Article 103726. https://doi.org/10.1016/j.mtbio.2026.103726

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103726

Keywords: neuropathic pain, microglia, AT-RvD1, specialized pro-resolving mediators, ANGPTL4, SUCLG1, propionate, liposomes, nanomedicine, neuroinflammation, drug delivery, spinal cord